Brandonne Rankin Brandonne Rankin

CURESHANK COMMUNITY NEWS: AUGUST 2025

In this issue of CureSHANK Community News, we’ll tell you about a milestone hire for our CureSHANK team, key takeaways from our second annual Phelan-McDermid Syndrome Drug Development Symposium (PMSDDS), JAG201 clinical trial updates, surprising findings from our study of genetic testing labs, project news, and more.

Get the full story here: conta.cc/45rWnK8

Read More
CureSHANK CureSHANK

CureSHANK & InnoSer Launch License‑Free Preclinical Platform for Phelan‑McDermid Syndrome

We are pleased to announce the launch of the first-ever license-free, gold-standard SHANK3 mouse model. By Q4 2025, this mouse model's availability will bypass the financial barriers posed by licensing fees. We will soon add a customizable preclinical mouse testing service with a partner CRO.

Combined, these tools will save companies tens of thousands of dollars and up to an entire year of work. Stay tuned for more announcements on this project soon!

Read More
Geraldine Bliss Geraldine Bliss

Pioneering Progress: Insights from ASGCT 2025 on the Future of PMS Therapeutics

Last week, Geraldine Bliss attended the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans on behalf of CureSHANK. Her participation reflects our unwavering commitment to staying at the forefront of research and innovation for the Phelan-McDermid syndrome (PMS) community. ASGCT is the premier international forum for advancements in gene and cell therapy, and Geraldine’s presence ensured that the unique needs of our community were represented in critical conversations. Her key takeaways—from gene editing to emerging delivery strategies—offer an invaluable window into the promising (and complex) path ahead for PMS therapeutics.

Read More
Newsletters CureSHANK Newsletters CureSHANK

Newsletter: Fall 2023

Registration is now open for our Fall 2023 Community webinar on Thursday, October 5 at 8pmEST/5pmCST. Please join us to learn about what we have accomplished so far in 2023 (including updates from our recent Epilepsy meeting); what we are planning for the future; and how you can get involved!

Read More